A Dose-range Study to Assess the Safety & Immunogenicity of a Novel HPV Vaccine When Administered Intramuscularly According to a 3-dose Schedule (0,1,6-mth) in Healthy Adult Females (18-25 Yrs of Age)

Inclusion Criteria:

- A woman between, and including, 18 and 25 years of age at the time of the first
vaccination.

- Written informed consent from the subject prior to enrolment.

- Subject must be free of obvious health problems.

- Subject must be of non-childbearing potential and have had no more than 6 lifetime
sexual partners.

Exclusion Criteria:

- Pregnant or breastfeeding.

- A woman planning to become pregnant or planning to discontinue contraceptive
precautions during approximately the first nine months of the study (Month 0-8).

- Known acute or chronic, clinically significant pulmonary, cardiovascular, neurologic,
hepatic or renal functional abnormality.

- History of chronic condition(s) requiring treatment such as cancer, chronic hepatitis
or kidney disease(s), diabetes, or autoimmune disease.

- Previous vaccination against human papillomavirus (HPV)